August 30, 2023 02:25 PM EDT

The cost of Wegovy: $1.1M to prevent one major cardiovascular event, Airfinity says

Katherine Lewin

News Reporter

The impact of Novo Nordisk’s GLP-1 semaglutide on cardiovascular health was received with great fanfare earlier this month, with the Danish pharma touting a 20 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The cost of Wegovy: $1.1M to prevent one major cardiovascular event, Airfinity says

Katherine Lewin

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Novartis claims best earnings in years, validating shift to pure-play strategy

Roche separates CFO, informatics posts; Lilly execs land at Kailera, Neurocrine

Vertex's non-opioid pain drug is approved by FDA, bringing first of new class to market

Friday IPO doubleheader from Maze and Metsera brings life to biotech debuts

AbbVie raises Skyrizi and Rinvoq estimates, predicts $31B in 2027 sales

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

The cost of We­govy: $1.1M to pre­vent one ma­jor car­dio­vas­cu­lar event, Airfin­i­ty says

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

The cost of Wegovy: $1.1M to prevent one major cardiovascular event, Airfinity says